Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shelley R Salpeter

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Expert Opinion on Drug Safety|April 23, 2010
An update on the safety of long-acting beta-agonists in asthma patients using inhaled corticosteroidsShelley R Salpeter
Canadian Family Physician Medecin De Famille Canadien|September 18, 2007
Rebuttal: should we avoid beta-agonists for moderate and severe chronic obstructive pulmonary disease? YesShelley R Salpeter
Drugs|October 2, 2009
Do inhaled anticholinergics increase or decrease the risk of major cardiovascular events?: a synthesis of the available evidenceShelley R Salpeter
Canadian Family Physician Medecin De Famille Canadien|September 18, 2007
Should we avoid beta-agonists for moderate and severe chronic obstructive pulmonary disease? YESShelley R Salpeter
International Journal of Chronic Obstructive Pulmonary Disease|November 30, 2007
Bronchodilators in COPD: impact of beta-agonists and anticholinergics on severe exacerbations and mortalityShelley R Salpeter
Drugs & Aging|April 16, 2004
Cardiovascular safety of beta(2)-adrenoceptor agonist use in patients with obstructive airway disease: a systematic reviewShelley R Salpeter
Clinical Reviews in Allergy & Immunology|November 7, 2006
Systematic review of clinical outcomes in chronic obstructive pulmonary disease: beta-agonist use compared with anticholinergics and inhaled corticosteroidsShelley R Salpeter, Nicholas S Buckley
Infection Control and Hospital Epidemiology|January 8, 2005
Screening and treatment of latent tuberculosis among healthcare workers at low, moderate, and high risk for tuberculosis exposure: a cost-effectiveness analysisShelley R Salpeter, Edwin E Salpeter
Drugs & Aging|May 6, 2015
A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the EvidenceJacob S Buckley, Shelley R Salpeter
Heart Failure Monitor|January 16, 2004
Beta-blocker use in patients with congestive heart failure and concomitant obstructive airway disease: moving from myth to evidence-based practiceThomas M Ormiston, Shelley R Salpeter
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Expert Opinion on Drug Safety|April 23, 2010
An update on the safety of long-acting beta-agonists in asthma patients using inhaled corticosteroidsShelley R Salpeter
Canadian Family Physician Medecin De Famille Canadien|September 18, 2007
Rebuttal: should we avoid beta-agonists for moderate and severe chronic obstructive pulmonary disease? YesShelley R Salpeter
Drugs|October 2, 2009
Do inhaled anticholinergics increase or decrease the risk of major cardiovascular events?: a synthesis of the available evidenceShelley R Salpeter
Canadian Family Physician Medecin De Famille Canadien|September 18, 2007
Should we avoid beta-agonists for moderate and severe chronic obstructive pulmonary disease? YESShelley R Salpeter
International Journal of Chronic Obstructive Pulmonary Disease|November 30, 2007
Bronchodilators in COPD: impact of beta-agonists and anticholinergics on severe exacerbations and mortalityShelley R Salpeter
Drugs & Aging|April 16, 2004
Cardiovascular safety of beta(2)-adrenoceptor agonist use in patients with obstructive airway disease: a systematic reviewShelley R Salpeter
Clinical Reviews in Allergy & Immunology|November 7, 2006
Systematic review of clinical outcomes in chronic obstructive pulmonary disease: beta-agonist use compared with anticholinergics and inhaled corticosteroidsShelley R Salpeter, Nicholas S Buckley
Infection Control and Hospital Epidemiology|January 8, 2005
Screening and treatment of latent tuberculosis among healthcare workers at low, moderate, and high risk for tuberculosis exposure: a cost-effectiveness analysisShelley R Salpeter, Edwin E Salpeter
Drugs & Aging|May 6, 2015
A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the EvidenceJacob S Buckley, Shelley R Salpeter
Heart Failure Monitor|January 16, 2004
Beta-blocker use in patients with congestive heart failure and concomitant obstructive airway disease: moving from myth to evidence-based practiceThomas M Ormiston, Shelley R Salpeter
Pageof 4